GE HealthCare Technologies Inc. (NASDAQ:GEHC) received a price target increase from Barclays to $87, following a solid Q4 2025 beat and optimistic 2026 outlook. Stifel also raised its price target to $98 with a Buy rating, while Morgan Stanley increased its target to $85 with an Equal Weight rating based on strong demand and performance.

GEHC develops healthcare products and solutions in the US, Canada, and globally. Despite its potential, other AI stocks may offer better upside and lower risk. For an undervalued AI stock with potential benefits from tariffs and onshoring, check out our report on the best short-term AI stock.

Barclays, Stifel, and Morgan Stanley have all recently raised their price targets for GE HealthCare Technologies Inc. (GEHC) based on strong performance and positive outlooks for 2026. The company continues to show robust demand and growth potential in the healthcare sector.

Read more at Yahoo Finance: Barclays Raises GE HealthCare (GEHC) PT to $87 Following Q4 Beat, Strong 2026 Outlook